Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
NCT01940965 on ClinicalTrials.gov · last registry update 2015-08-04
Finished July 2015, after enrolling 294 people. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P3
- Drug
- lixisenatideSoliqua, Adlyxin
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Enrollment
- 294
- Started
- 2013-09
- Primary completion
- 2015-07 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as COMPLETED, P3 |
Primary outcome
Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.